Bank of New York Mellon Corp Trims Holdings in West Pharmaceutical Services, Inc. $WST

Bank of New York Mellon Corp trimmed its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,662,035 shares of the medical instruments supplier’s stock after selling 242,674 shares during the quarter. Bank of New York Mellon Corp’s holdings in West Pharmaceutical Services were worth $732,432,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth approximately $25,000. Private Trust Co. NA increased its holdings in West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth approximately $31,000. CYBER HORNET ETFs LLC purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. Finally, Torren Management LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth approximately $34,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Up 1.4%

WST stock opened at $316.66 on Thursday. The firm has a fifty day moving average price of $288.08 and a 200 day moving average price of $268.56. West Pharmaceutical Services, Inc. has a fifty-two week low of $206.80 and a fifty-two week high of $330.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The firm has a market cap of $22.37 billion, a PE ratio of 42.33, a price-to-earnings-growth ratio of 2.61 and a beta of 1.18.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. West Pharmaceutical Services’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period last year, the firm posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

West Pharmaceutical Services declared that its board has approved a stock repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

WST has been the subject of several analyst reports. UBS Group reissued a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. Stephens reiterated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, Evercore reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $331.91.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.